<DOC>
	<DOCNO>NCT02435927</DOCNO>
	<brief_summary>This Phase I , open-label , dose escalation study ASLAN001 give combination CAPOX mFolfox6 , patient metastatic solid tumour , suitable receive CAPOX mFolfox6 , tumours dysregulated EGFR HER2 signaling .</brief_summary>
	<brief_title>ASLAN001 Combination With Oxaliplatin Capecitabine Oxaliplatin 5-FU With Leucovorin</brief_title>
	<detailed_description>The study use standard 3+3 design determine MTD ( maximum tolerate dose ) ASLAN001 combination fix dose Oxaliplatin/Capecitabine ( CAPOX ) 5-FU/leucovorin ( mFolfox6 ) . MTD ASLAN001 combination CAPOX first determine follow combination mFolfox6 . The recommended Phase II dose high dose combination therapy consider tolerate 6 patient .</detailed_description>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Patients metastatic solid tumour eligible treatment oxaliplatin combination capecitabine / 5FU ( fluorouracil ) leucovorin progress follow standard therapy patient EGFR ( epidermal growth factor receptor ) HER2 dysregulated tumour . 2 . Patients partial gastrectomy may allow participate study long take oral medication meet inclusion/exclusion criterion . 3 . Eastern Cooperative Oncology Group performance status 0 1 . 4 . Adequate organ hematological function evidence follow laboratory study within 14 day prior enrolment : • Hematological function , follow : Absolute neutrophil count ≥ 1.5 x 109/L . Platelet count ≥ 100 x 109/L . Hemoglobin ≥ 9 g/dL . • Coagulation function , follow : Prothrombin time activate partial thromboplastin time ≤ 1.5 x upper limit normal ( ULN ) per institutional laboratory normal range . • Renal function , follow : Creatinine clearance ≥ 50 mL/min calculate CockcroftGault formula . • Hepatic function , follow : Total bilirubin ≤ 1.5 x ULN . Aspartate aminotransferase alanine aminotransferase ≤ 2.5 x ULN ( ≤ 5 x ULN liver metastasis present ) . 5 . Patients undergo mandatory biopsy dose expansion nonDLT cohort follow : know HER2 EGFR dysregulation Patients T790M mutation exclude . Coexpression HER2 EGFR 6 . Archival tumour sample available molecular profiling , unless undergo tumour biopsy part trial . 1 . Patients persistent gastric outlet obstruction , complete dysphagia feed jejunostomy . 2 . Patients receive proton pump inhibitor H2 antagonist establish , symptomatic gastro duodenal ulceration gastroesophageal reflux disease . H2 antagonist prescribe DLT ( doselimiting toxicity ) period ( first 2 cycle ) discretion investigator . 3 . Patients unresolved toxicity grade 2 prior anticancer therapy exclude alopecia . 4 . Untreated symptomatic central nervous system metastasis . Patients treat brain metastasis stable 3 month eligible enroll . 5 . Major surgical procedure within 28 day prior enrolment . 6 . Clinically significant cardiovascular disease symptomatic uncontrolled . 7 . Known active infection human immunodeficiency virus , hepatitis B C. 8 . Pregnant breastfeeding female . 9 . Treatment follow anticancer therapy prior first dose study drug within state timeframes Cyclical chemotherapy within period time short cycle length use treatment . Exception weekly chemotherapy regimen , minimum 2 week washout last dose require . Biological therapy ( e.g. , antibody ) within period time ≤ 5 t1/2 ≤ 4 week , whichever short , prior start study drug Continuous intermittent small molecule therapeutic within period time ≤ 5 t1/2 ≤ 4 week ( whichever short ) prior start study drug Any investigational agent within period time ≤ 5 t1/2 less cycle length use treatment ≤ 4 week ( whichever shortest ) prior start study drug Wide field radiotherapy ≤ 4 week limited field radiation palliation ≤ 2 week prior start study drug Previous combination therapy xeloda oxaliplatin within 6 month study treatment . Previous combination therapy Oxaliplatin , 5FU Leucovorin ( mFolfox6 ) within 6 month study treatment</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>